BACKGROUND: Most patients with locally advanced esophageal cancer requiring neoadjuvant therapy have significant dysphagia. OBJECTIVE: To report our experience in using a fully covered self-expandable metal stent (FCSEMS) to treat malignant dysphagia and for maintenance of nutritional support during neoadjuvant therapy. DESIGN: Retrospective study. SETTING: Two tertiary-care referral centers. PATIENTS: This study involved 55 patients with locally advanced esophageal cancer (50 adenocarcinoma, 5 squamous cell carcinoma). Forty-three patients were men, and the mean age was 65.8 years. INTERVENTION: EUS followed by FCSEMS placement. MAIN OUTCOME MEASUREMENTS: Procedural success, dysphagia scores, patient weights, stent migration, and stent-related complications. RESULTS: All stents were successfully placed. Tumors were located in the middle esophagus (n = 10) and distal esophagus (n = 45). The mean dysphagia score obtained at 1 week after stent placement had improved significantly from baseline (2.4 and 1, respectively; P < .001). Patients maintained their weights at 1 month follow-up when compared with baseline (153 and 149 pounds, respectively; P = .58). Immediate complications included chest discomfort in 13 patients; 2 patients required stent removal because of intractable pain. One patient had stent removal because of significant acid reflux. Stent migration occurred at some point in 17 of 55 patients (31%). There was a delayed perforation in 1 patient. Because of disease progression or the discovery of metastasis after neoadjuvant therapy, only 8 of 55 patients underwent curative surgery. LIMITATIONS: Retrospective study. CONCLUSION: Placement of FCSEMSs in patients with locally advanced esophageal cancer significantly improves dysphagia and allows for oral nutrition during neoadjuvant therapy. FCSEMSs appear to be effective for palliating dysphagia. Migration was not associated with injury or harm to the patient and usually represented a positive response to neoadjuvant therapy. Few patients undergoing stenting in this situation ultimately undergo surgery because of disease progression or poor operative candidacy.
BACKGROUND: Most patients with locally advanced esophageal cancer requiring neoadjuvant therapy have significant dysphagia. OBJECTIVE: To report our experience in using a fully covered self-expandable metal stent (FCSEMS) to treat malignant dysphagia and for maintenance of nutritional support during neoadjuvant therapy. DESIGN: Retrospective study. SETTING: Two tertiary-care referral centers. PATIENTS: This study involved 55 patients with locally advanced esophageal cancer (50 adenocarcinoma, 5 squamous cell carcinoma). Forty-three patients were men, and the mean age was 65.8 years. INTERVENTION: EUS followed by FCSEMS placement. MAIN OUTCOME MEASUREMENTS: Procedural success, dysphagia scores, patient weights, stent migration, and stent-related complications. RESULTS: All stents were successfully placed. Tumors were located in the middle esophagus (n = 10) and distal esophagus (n = 45). The mean dysphagia score obtained at 1 week after stent placement had improved significantly from baseline (2.4 and 1, respectively; P < .001). Patients maintained their weights at 1 month follow-up when compared with baseline (153 and 149 pounds, respectively; P = .58). Immediate complications included chest discomfort in 13 patients; 2 patients required stent removal because of intractable pain. One patient had stent removal because of significant acid reflux. Stent migration occurred at some point in 17 of 55 patients (31%). There was a delayed perforation in 1 patient. Because of disease progression or the discovery of metastasis after neoadjuvant therapy, only 8 of 55 patients underwent curative surgery. LIMITATIONS: Retrospective study. CONCLUSION: Placement of FCSEMSs in patients with locally advanced esophageal cancer significantly improves dysphagia and allows for oral nutrition during neoadjuvant therapy. FCSEMSs appear to be effective for palliating dysphagia. Migration was not associated with injury or harm to the patient and usually represented a positive response to neoadjuvant therapy. Few patients undergoing stenting in this situation ultimately undergo surgery because of disease progression or poor operative candidacy.
Authors: Juliana Yang; Ali A Siddiqui; Thomas E Kowalski; David E Loren; Ammara Khalid; Ayesha Soomro; Syed M Mazhar; Julian Rosé; Laura Isby; Michel Kahaleh; Ankush Kalra; Alex M Sarkisian; Nikhil A Kumta; Jose Nieto; Reem Z Sharaiha Journal: Surg Endosc Date: 2016-08-05 Impact factor: 4.584
Authors: Marina Ulla; Ernestina Gentile; Ezequiel Levy Yeyati; Maria L Diez; Demetrio Cavadas; Ricardo D Garcia-Monaco; Pablo R Ros Journal: World J Gastrointest Oncol Date: 2013-12-15
Authors: S Mão-de-Ferro; M Serrano; S Ferreira; I Rosa; P Lage; D P Alexandre; J Freire; L Mirones; R Casaca; A Bettencourt; A D Pereira Journal: Eur J Clin Nutr Date: 2015-12-16 Impact factor: 4.016